. 2022 Apr 7;36(5):e24390. doi: 10.1002/jcla.24390

TABLE 4.

Overall and disease‐free survival times of thyroid cancer patients

Biomarker	Expression	Disease‐free survival (months)	p‐value	Overall survival (months)	p‐value
PVT1 gene	Low	48.8 (29.5–68.2)	0.96	69.6 (57.1–82.3)	0.91
PVT1 gene	High	49.6 (38.0–61.2)	0.96	73.8 (66.9–80.7)	0.91
p53 protein	Low	39.1 (24.6–53.6)	0.71	55.5 (45.8–65.2)	<0.001
p53 protein	High	51.7 (6.06–39.8)	0.71	80.2 (74.2–86.3)	<0.001
bcl2 protein	Low	51.7 (38.4–64.9)	0.49	73.5 (65.2–81.7)	0.95
bcl2 protein	High	45.4 (30.9–59.9)	0.49	71.1 (60.8–81.3)	0.95
PD−1 protein	Low	55.5 (39.1–71.9)	0.58	77.7 (71.7–83.6)	0.28
PD−1 protein	High	49.3 (37.1–61.5)	0.58	71.5 (62.9–80.1)	0.28
PD‐L1 tumor	Low	50.9 (38.8–63.0)	0.73	79.8(73.6–86.1)	0.018
PD‐L1 tumor	High	48.5 (30.1–66.8)	0.73	62.9 (51.7–74.1)	0.018
PD‐L1 lymphocyte	Low	59.7 (45.6–73.7)	0.08	71.9 (62.9–80.9)	0.63
PD‐L1 lymphocyte	High	39.6 (26.6–52.5)	0.08	71.9 (64.6–79.1)	0.63
BRAF mutation	Negative	41.9 (28.7–55.1)	0.11	72.2 (65.2–79.3)	0.92
BRAF mutation	Positive	57.9 (42.4–73.3)	0.11	73.1 (61.4–84.7)	0.92

Log Rank (Mantel‐Cox) test was used. Data are presented as mean survival estimates in months and 95% confidence interval. Bold values indicate significance at p‐value <0.05.